Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$9.8M
12M shares
52-week range
$0.55 – $2.22
16% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
10.56%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $583.2K | $1.5M | $0 |
| Cost of revenue | $8.3K | $170.3K | $229.6K | $271.7K | $16.4M | $7.1K | $9.4M | $0 |
| Gross profit | −$8.3K | −$170.3K | −$229.6K | −$271.7K | −$16.4M | $576.2K | −$7.9M | $0 |
| Gross margin | — | — | — | — | — | 98.8% | -523.2% | — |
| R&D | $14.2M | $21.0M | $37.9M | $23.9M | $92.4M | $7.6M | $9.4M | $7.0M |
| Operating income | −$16.5M | −$29.5M | −$52.8M | −$37.4M | −$113.4M | −$15.5M | −$14.3M | −$13.2M |
| EBITDA | −$15.5M | −$27.9M | −$53.2M | −$36.9M | −$37.4M | −$14.3M | −$12.9M | −$12.6M |
| Net income | −$15.5M | −$28.1M | −$53.9M | −$36.5M | −$112.7M | −$14.3M | −$13.0M | −$12.6M |
| Net margin | — | — | — | — | — | -2449.6% | -862.4% | — |
| EPS (diluted) | -22.06 | -26.28 | -50.61 | -34.88 | -1359.79 | -3.95 | -2.35 | -1.93 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-0.69 | $-0.78–$-0.54 | 3 |
| 2027 | $2M | $-0.66 | $-0.88–$-0.35 | 3 |
| 2028 | $4M | $-0.73 | $-1.17–$-0.42 | 4 |
| 2029 | $12M | $-0.47 | $-0.47–$-0.47 | 2 |
Forward consensus · source: Financial Modeling Prep
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
www.aprea.comNo one on the platform currently holds APRE.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 25,100 | $19.1K |
| Execution date | Ratio |
|---|---|
| 2023-02-13 | 1-for-20reverse |
| 2018-12-27 | 1-for-1000reverse |
| 2011-09-13 | 1-for-500reverse |
No one on the platform has traded APRE yet.
| $7M |
| — |
| CELZCreative Medical Technology Holdings, Inc. | $0.81 | -32.48% | $2M | — |
| GLTODamora Therapeutics, Inc. | $21.58 | -3.36% | $34M | — |
Source: Financial Modeling Prep · peers by sector/industry
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology ONCO.AQL $ONNVF $AZN $APRE $BOLD $FHTX https://ibn.fm/zrVjp
View on StockTwits ↗$APRE authorized a shareholder‑approved reverse stock split of its common stock.
View on StockTwits ↗$APRE 08:08 on Jun. 01 2026 Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors #tradeideas
View on StockTwits ↗$APRE Added here just buyers on low volume these are the stocks I love
View on StockTwits ↗$APRE 13 G filled on 2026-05-15: Vestal Point Capital, LP 22,654,832 shares 9.9 % ownership 👃👀 https://www.sec.gov/Archives/edgar/data/1781983/000090266426002544/xslSCHEDULE_13G_X02/primary_doc.xml
View on StockTwits ↗$APRE https://anachart.com/wp-content/uploads/2026/05/1778770900_soc-img.jpg
View on StockTwits ↗$APRE 👃👀 https://www.stocktitan.net/news/APRE/aprea-therapeutics-reports-first-quarter-2026-financial-results-and-34l1uxshvz6p.html
View on StockTwits ↗$IMMP $APRE $INAB at ASCO as well. NO POSITION... just watching for now
View on StockTwits ↗$APRE .... 👃👀 https://x.com/i/status/2052407226862596569
View on StockTwits ↗$APRE PT $ 5 👃👀 https://x.com/i/status/2052799398229545466
View on StockTwits ↗$APRE .. $.96 key catalyst update coming up at #ASCO26. Discussed this in my biotech podcast. Lots of catalysts. Biopharmcatalyst Mid-Year 2026 Catalysts.. https://www.youtube.com/watch?v=tSk02XN5zgo
View on StockTwits ↗Oppenheimer backs $APRE with $5 target. Its cancer drug shows early promise, and low valuation offers big upside potential. https://notreload.xyz/xy/why-oppenheimer-is-bullish-on-tiny-biotech-aprea-therapeutics/
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.